Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Human Metabolome Technologies, Inc. ( (JP:6090) ).
Human Metabolome Technologies, Inc. reported a significant increase in its quarterly financial results for March 2025, with net sales rising by 13.5% and operating profit increasing by 40.5% compared to the previous year. The company’s strong performance is reflected in its improved capital adequacy ratio and comprehensive income, indicating robust financial health and potential positive implications for stakeholders.
More about Human Metabolome Technologies, Inc.
Human Metabolome Technologies, Inc. operates in the general business category and is listed on the Tokyo Growth stock exchange. The company focuses on metabolome analysis, which involves studying small molecules in biological samples to understand metabolic processes. Their primary market includes research institutions and pharmaceutical companies.
Average Trading Volume: 8,066
Technical Sentiment Signal: Buy
Current Market Cap: Yen3.97B
For an in-depth examination of 6090 stock, go to TipRanks’ Stock Analysis page.